Compared to SII or other indicators, the differences in PSA levels between the prostate cancer group and the benign prostatic hyperplasia group are more pronounced, and PSA shows higher predictive efficacy for metastatic prostate cancer. This evidence concerns the gene KLK3 and prostate cancer.